Phase 2a Randomized, Controlled, Multi-center, Open-label Dose Ranging Proof of Concept Study to Evaluate the Safety, Tolerability and Antiviral Activity of AIC-001 Over 14 Days of Dosing in Patients With Positive HCMV Viremia Under the Conditions of a Pre-emptive Strategy.
Latest Information Update: 21 Sep 2015
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors AiCuris
Most Recent Events
- 30 Aug 2011 New trial record